114780-06-2

Basic information

• Product Name: 4-CHLORO-N,N-DIMETHYL-PYRIDINE-2-CARBOXAMIDE
• Synonyms: 4-CHLORO-N,N-DIMETHYL-PYRIDINE-2-CARBOXAMIDE;4-Chloro-N,N-dimethylpicolinamide;2-Pyridinecarboxamide, 4-chloro-N,N-dimethyl-
• CAS NO: 114780-06-2
• Molecular Formula: C₈H₉ClN₂O
• Molecular Weight: 184.62
• Product Categories: Pyridines
• Mol File: 114780-06-2.mol

Chemical Properties

• Boiling Point: 323.5 °C at 760 mmHg
• Flash Point: 149.4 °C
• Appearance: /
• Density: 1.231 g/cm³
• Vapor Pressure: 0.000261mmHg at 25°C
• Refractive Index: 1.548
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.67±0.10(Predicted)
• CAS DataBase Reference: 4-CHLORO-N,N-DIMETHYL-PYRIDINE-2-CARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-N,N-DIMETHYL-PYRIDINE-2-CARBOXAMIDE(114780-06-2)
• EPA Substance Registry System: 4-CHLORO-N,N-DIMETHYL-PYRIDINE-2-CARBOXAMIDE(114780-06-2)

Safety Data

• Hazardous Substances Data: 114780-06-2(Hazardous Substances Data)

Usage

Uses

Used in Scientific Research:
4-Chloro-N,N-Dimethyl-Pyridine-2-Carboxamide is used as a research chemical for the synthesis of other complex compounds and drugs. It plays a crucial role in the development of new pharmaceuticals and bioactive molecules.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 4-Chloro-N,N-Dimethyl-Pyridine-2-Carboxamide is used as an intermediate or building block in the synthesis of various drugs. Its unique chemical structure allows for the creation of new therapeutic agents with potential applications in medicine.

InChI:InChI=1/C8H9ClN2O/c1-11(2)8(12)7-5-6(9)3-4-10-7/h3-5H,1-2H3

Upstream product

• 51727-15-2 4-chloro-2-pyridine carboxylic acid chloride hydrochloride 
• 124-40-3 dimethyl amine 
• 98-98-6 2-Picolinic acid 
• 220000-87-3 4-chloro-N-methylpicolinamide 
• 74-88-4 methyl iodide 
• 53750-66-6 4-chloro-pyridine-2-carbonyl chloride 

Downstream Products

• 284462-37-9 4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide 
• 284462-86-8 4-(4-aminophenoxy)-N,N-dimethylpicolinamide 
• 611226-20-1 4-(4-Amino-3-nitro-phenoxy)-pyridine-2-carboxylic acid dimethylamide 

Relevant articles and documents

3-Aryl-1,2,4-oxadiazole Derivatives Active Against Human Rhinovirus

The human rhinovirus (hRV) is the causative agent of the common cold that often aggravates respiratory complications in patients with asthma or chronic obstructive pulmonary disease. The high rate of mutations and variety of serotypes are limiting the development of anti-hRV drugs, which emphasizes the need for the discovery of novel lead compounds. Previously, we identified antiviral compound 1 that we used here as the starting material for developing a novel compound series with high efficacy against hRV-A and -B. Improved metabolic stability was achieved by substituting an ester moiety with a 1,2,4-oxadiazole group. Specifically, compound 3k exhibited a high efficacy against hRV-B14, hRV-A21, and hRV-A71, with EC50 values of 66.0, 22.0, and 3.7 nM, respectively, and a relevant hepatic stability (59.6 and 40.7% compound remaining after 30 min in rat and human liver microsomes, respectively). An in vivo study demonstrated that 3k possessed a desirable pharmacokinetic profile with low systemic clearance (0.158 L·h-1·kg-1) and modest oral bioavailability (27.8%). Hence, 3k appears to be an interesting candidate for the development of antiviral lead compounds.

SORAFENIB ANALOGS AND USES THEREOF

The present invention provides, inter alia, compounds according to formula I. Also provided are pharmaceutical compositions and kits containing such compounds. Methods for using such compounds, compositions, and kits for treating a subject having system xc-, dysregulation for activating ferroptosis, for inhibiting system xc- in a cell, and for monitoring treatment of a subject having system xc- dysregulation are provided as well.

Substituted benzazoles and methods of their use as inhibitors of Raf kinase

New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.